Nanox AI secures UK reseller deal for bone health software
Nanox AI, a subsidiary of Nanox Imaging Ltd., has entered into an exclusive three-year reseller agreement with Vertec Scientific Ltd. for its HealthOST bone solution in the UK. HealthOST is an FDA-cleared and UKCA/CE-marked AI software that analyzes routine CT scans to assess musculoskeletal disease of the spine, including osteoporosis, without requiring additional imaging or patient time. This deal aims to expand the reach of Nanox AI's technology in the UK market, following a recommendation by the National Institute for Health and Care Excellence for similar AI technologies in opportunistic detection of vertebral fragility fractures.
Nanox's bone software analyzes routine CT scans without extra radiation or patient time
Nanox's AI subsidiary has signed an exclusive three-year sales reseller agreement with Vertec Scientific for its HealthOST bone solution in the UK. HealthOST is an FDA-cleared and UKCA/CE-marked AI software that analyzes routine CT scans to assess spine-related musculoskeletal diseases like osteoporosis, without requiring additional imaging or radiation. This partnership aims to expand the reach of AI-driven bone health assessment to healthcare providers across the UK, leveraging Vertec Scientific's established presence in DXA and bone health solutions.
Nano-X (NASDAQ: NNOX) warns on cash runway before vote to boost share pool
Nano-X Imaging Ltd. (NASDAQ: NNOX) is holding its 2026 annual general meeting on September 17, 2026, where shareholders will vote on increasing the authorized share capital by 50 million ordinary shares due to the company's limited cash runway. Management disclosed that current cash and equivalents as of March 31, 2026, are insufficient to support operations for at least one year, raising substantial doubt about its ability to continue as a going concern. The proposal aims to provide flexibility for future financing, strategic transactions, equity compensation, and Nasdaq compliance.
Nanox and Vertec Scientific Enter Exclusive Sales Reseller
Nanox AI has partnered with Vertec Scientific Ltd. through an exclusive sales reseller agreement to commercialize its Nanox.AI bone solution (HealthOST) in the United Kingdom. This three-year agreement includes minimum annual license commitments and aims to expand the reach of AI-driven bone health assessment. HealthOST is an FDA-cleared and UKCA/CE-marked AI software that analyzes routine CT scans to detect musculoskeletal diseases like osteoporosis.
Nano-X Imaging faces legal battles ahead of Q3 earnings with expected loss and strong balance sheet.
Nano-X Imaging Ltd. is preparing to report its Q3 earnings, with analysts projecting a loss of $0.16 per share and revenues of $5.38 million. The company is simultaneously dealing with several class-action lawsuits regarding alleged securities law violations. Despite an unprofitable P/E ratio, Nano-X demonstrates financial stability through a low debt-to-equity ratio and a strong current ratio.
NNOX Reiterated by Cantor Fitzgerald -- Price Target Maintained at $5.00
Cantor Fitzgerald has reiterated its Overweight rating for Nano X Imaging (NNOX), maintaining a price target of $5.00, suggesting confidence in the company despite varying analyst opinions. Although NNOX is currently unprofitable, its GF Value of $10.16 indicates it is significantly undervalued by 90.2%. However, its low GF Score of 41/100, especially in profitability and growth, alongside a high Price-to-Sales ratio, presents a mixed picture for investors.
NNOX Q2'26 Earnings: EPS estimate is (0.16) USD
NANO-X IMAGING LTD (NNOX) is expected to announce its Q2'26 earnings on August 18, with an anticipated revenue of 5.39 million USD and an EPS of (0.16) USD. The article provides a detailed table comparing reported and estimated revenue and EPS figures for several quarters, highlighting past surprises.
Nano-X Imaging (NASDAQ: NNOX) Optimizes Nanox.AI Medical Imaging Framework for Intel Core Ultra Processors
Nano-X Imaging Ltd. (NASDAQ: NNOX) announced that its subsidiary Nanox.AI has optimized its medical imaging AI application framework for Intel Core Ultra processors using the Intel OpenVINO toolkit. This optimization enables healthcare facilities to deploy CT imaging AI applications on on-premise edge devices, keeping imaging data within their own infrastructure and bringing AI-enabled insights closer to the point of care. The framework aims to reduce dependence on cloud connectivity and support deployment within existing hospital infrastructure for identifying chronic conditions.
Nano-X Imaging (NASDAQ: NNOX) Optimizes Nanox.AI Medical Imaging Framework for Intel Core Ultra Processors
Nano-X Imaging Ltd. announced that its subsidiary, Nanox.AI Ltd., has optimized its medical imaging AI application framework for Intel Core Ultra processors using the Intel OpenVINO toolkit. This optimization allows healthcare facilities to deploy CT imaging AI applications on on-premise edge devices, keeping imaging data within their own infrastructure. The Nanox.AI solutions analyze CT scans to identify findings correlated with chronic conditions related to cardiac, liver, and bone health, bringing AI-enabled insights closer to the point of care while reducing reliance on cloud connectivity.
NNOX DEADLINE - FINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Nano-X Imaging Ltd. to Contact the Firm Today!
Bronstein, Gewirtz & Grossman, LLC is issuing a final reminder to stockholders of Nano-X Imaging Ltd. (NASDAQ:NNOX) about a class action lawsuit. The lawsuit alleges that Nano-X Imaging Ltd. and its officers made false and misleading statements regarding the company's operations and prospects between March 31, 2025, and April 17, 2026. Investors who suffered losses have until August 11, 2026, to request to be appointed as lead plaintiff.
Portnoy Law Firm Announces Class Action on Behalf of Nano-X Imaging Ltd. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Nano-X Imaging Ltd. (NASDAQ: NNOX) who purchased securities between March 31, 2025, and April 17, 2026. The lawsuit alleges that Nano-X overstated its efficiency, experienced misalignment between production and demand, and faced increased operating expenses, leading to misleading public statements. Investors have until August 11, 2026, to file a lead plaintiff motion.
NNOX Shareholder Alert: Nano-X Imaging Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for Nano-X Imaging Ltd. (NASDAQ: NNOX) investors, announcing a securities class action lawsuit. The lawsuit alleges that Nano-X Imaging Ltd. made materially false and misleading statements regarding its operational efficiency and product demand, leading to increased operating expenses and potential restructuring charges. Shareholders who purchased NNOX shares between March 31, 2025, and April 17, 2026, are encouraged to contact the firm, with a deadline to seek lead plaintiff appointment by August 11, 2026.
Nano-X Imaging (NNOX) CEO Erez Meltzer adds 9,443 shares via owned company
Nano-X Imaging Ltd. CEO Erez Meltzer indirectly purchased 9,443 Ordinary Shares on August 10, 2026, at $1.03 per share through his wholly-owned company, Oud Nof. This transaction increased Oud Nof's holdings to 45,443 shares, while Meltzer also directly holds 60,584 Ordinary Shares and multiple stock options. The purchase was not made under a Rule 10b5-1 trading plan.
Urgent Deadline for Shareholders who lost money in shares of Nano-X Imaging Ltd. (NASDAQ: NNOX)
Wolf Haldenstein Adler Freeman & Herz LLP reminds investors of Nano-X Imaging Ltd. (NASDAQ: NNOX) of a class action lawsuit with a lead plaintiff deadline of today, August 11, 2026. The lawsuit alleges that Nano-X overstated its operational efficiency and product demand, leading to significant financial losses for investors. This follows Nano-X's Q4 2025 financial results which reported a net loss and a $17.5 million impairment charge due to a restructuring initiative.
Nanox.AI Optimizes Medical Imaging AI Application Framework for Intel Core Ultra Processors with OpenVINO
Nanox.AI has optimized its medical imaging AI application framework for Intel Core Ultra processors using Intel’s OpenVINO toolkit. This optimization allows healthcare organizations to deploy CT imaging AI applications on-premise, reducing reliance on cloud connectivity and keeping data within their own infrastructure. The collaboration aims to bring AI-enabled imaging insights closer to the point of care, supporting preventive care management and improving clinical workflows.
NNOX EQUITY ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nano-X Imaging (NNOX) Investors of Securities Class Action Lawsuit Deadline on August 11, 2026
Faruqi & Faruqi, LLP is reminding investors of Nano-X Imaging (NNOX) about a securities class action lawsuit deadline on August 11, 2026. The lawsuit alleges that Nano-X made false and misleading statements regarding its operational efficiency, product demand, and financial health, leading to increased operating expenses and cash burn. Investors who purchased Nano-X securities between March 31, 2025, and April 17, 2026, and suffered losses are encouraged to contact the firm to discuss their legal options and the lead plaintiff process.
NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Nano-X Imaging Ltd. (NNOX) for alleged securities fraud, covering the period from March 31, 2025, to April 17, 2026. The lawsuit claims Nano-X made false and misleading statements regarding demand for its products and operational efficiency, leading to increased cash burn due to misalignment with customer demands. Investors who suffered losses during this period are encouraged to contact SBS Law to potentially lead the lawsuit, with a deadline of August 11, 2026, for lead plaintiff appointments.
Nano-X Deadline: NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit
Rosen Law Firm is reminding investors of Nano-X Imaging Ltd. (NASDAQ: NNOX) who purchased securities between March 31, 2025, and April 17, 2026, about the August 11, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Nano-X made false and misleading statements regarding its operational efficiency, product demand, and increasing operating expenses and cash burn, leading to investor damages. Investors can join the class action by contacting Rosen Law Firm.
Nano-X Deadline: NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit
Rosen Law Firm reminds purchasers of Nano-X Imaging Ltd. (NNOX) securities between March 31, 2025, and April 17, 2026, that the lead plaintiff deadline for a securities fraud lawsuit is August 11, 2026. The lawsuit alleges that Nano-X made false or misleading statements regarding its operational efficiency and demand, leading to increased operating expenses and cash burn. Investors who suffered losses are encouraged to contact Rosen Law Firm to explore their options to lead the class action.
Nano-X Deadline: NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between March 31, 2025, and April 17, 2026, about the August 11, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Nano-X made false and misleading statements regarding its operational efficiency, product demand, and financial health, leading to increased operating expenses and cash burn. Investors are encouraged to join the class action to seek compensation.
Nano-X Deadline: NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit
The Rosen Law Firm is reminding purchasers of Nano-X Imaging Ltd. (NASDAQ: NNOX) securities that the lead plaintiff deadline for a securities fraud lawsuit is August 11, 2026. Investors who bought Nano-X securities between March 31, 2025, and April 17, 2026, may be entitled to compensation. The lawsuit alleges that Nano-X overstated efficiency and demand, leading to increased operating expenses and potential restructuring charges.
NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Nano-X Imaging Ltd. (NASDAQ:NNOX) on behalf of investors who purchased securities between March 31, 2025, and April 17, 2026. The lawsuit alleges that Nano-X made materially false and misleading statements regarding its business operations, specifically overstating efficiency gains and demand for its products, leading to increased operating expenses and potential restructuring. Investors who suffered losses are encouraged to join the case by August 11, 2026, to potentially be appointed as lead plaintiff.
Nano-X Imaging Raises $8 Million in Registered Direct Offering Completed on August 7, 2026
Nano-X Imaging (NNOX) announced the completion of an $8 million registered direct offering on August 7, 2026, to a single institutional investor. The company issued 8 million ordinary shares or pre-funded warrants along with 8 million purchase warrants, with proceeds intended for working capital and general corporate purposes. This financing move comes amidst weak financial performance and a "Hold" analyst rating with a $3.00 price target.
Nano-X Imaging (NASDAQ: NNOX) completes $8.0M registered direct offering
Nano-X Imaging Ltd. (NNOX) has completed an $8.0 million registered direct offering with a single institutional investor. The offering included 8,000,000 ordinary shares (or pre-funded warrants) and 8,000,000 ordinary warrants, with proceeds intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners served as the sole placement agent, receiving a 5.0% cash fee.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2026 in Nano-X Imaging Ltd. Lawsuit - NNOX
SueWallSt is reminding investors of a lead plaintiff deadline of August 11, 2026, in a securities class action lawsuit against Nano-X Imaging Ltd. (NNOX). The lawsuit names CEO Erez Meltzer and former CFO Ran Daniel as individual defendants, alleging they made misleading statements regarding the company's manufacturing efficiency and operational scaling, leading to a significant stock drop after an impairment charge and restructuring announcement. The complaint specifically charges violations of Section 20(a) of the Securities Exchange Act and false Sarbanes-Oxley certifications.
Nano-X Imaging Raises $8 Million in Registered Direct Offering to Fund Working Capital and Corporate Initiatives
Nano-X Imaging Ltd. (NASDAQ: NNOX) has secured an $8 million registered direct offering with a long-term institutional investor. The financing, involving the sale of 8 million ordinary shares or prefunded warrants and accompanying warrants, aims to provide working capital and support the company's corporate initiatives. This capital raise will help Nano-X advance its integrated healthcare platform, which includes imaging hardware, AI-based solutions, and cloud services, to expand access to preventive medical imaging.
Pomerantz Law Firm Announces the Filing of a Class Action Against Nano-X Imaging Ltd. and Certain Officers - NNOX
Pomerantz LLP has filed a class action lawsuit against Nano-X Imaging Ltd. (NASDAQ: NNOX) and certain officers, alleging materially false and misleading statements were made to investors between March 31, 2025, and April 17, 2026. The lawsuit claims Nano-X overstated efficiency gains and demand, leading to increased operating expenses and cash burn, which was later revealed by significant impairment charges and a leadership change. Investors who purchased Nano-X securities during this period have until August 11, 2026, to seek appointment as Lead Plaintiff.
NNOX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nano-X Imaging Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Nano-X Imaging Ltd. (NASDAQ:NNOX) and its officers. The lawsuit alleges that Nano-X made materially false and misleading statements about its business, operations, and prospects, specifically overstating efficiency and demand while experiencing increased operating expenses and cash burn. Shareholders who purchased Nano-X securities between March 31, 2025, and April 17, 2026, have until August 11, 2026, to request to be appointed lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges Nano-X Imaging Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Nano-X Imaging Ltd. (NASDAQ: NNOX) and its officers, alleging violations of federal securities laws. The lawsuit claims that Nano-X made materially false and misleading statements regarding its operations, overstating efficiency gains and demand, while facing increased operating expenses and cash burn due to poor alignment between production and demand. Investors who purchased Nano-X securities between March 31, 2025, and April 17, 2026, are encouraged to join the case and have until August 11, 2026, to request lead plaintiff appointment.
Nano-X Imaging raises $8 million in registered direct offering
Nano-X Imaging Ltd. (NASDAQ:NNOX) has secured $8 million through a registered direct offering with a single institutional investor. The offering involved the sale of 8,000,000 ordinary shares and warrants to purchase an equal number of additional shares, priced at $1.00 per combined share and warrant. The net proceeds will be allocated towards working capital and general corporate purposes for the medical imaging technology company.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2026 in Nano-X Imaging Ltd. Lawsuit - NNOX
SueWallSt is reminding investors of Nano-X Imaging Ltd. (NASDAQ: NNOX) about an August 11, 2026, deadline to apply for lead plaintiff in a securities class action lawsuit. The lawsuit names CEO Erez Meltzer and CFO Ran Daniel as individual defendants, alleging they made misleading statements regarding manufacturing efficiency and operational scaling, which led to a significant share price drop after a $17.5 million impairment charge and restructuring disclosure. The complaint asserts the officers violated Section 20(a) of the Securities Exchange Act and made false Sarbanes-Oxley certifications.
Nano-X Imaging raises $8 million in registered direct offering By Investing.com
Nano-X Imaging Ltd. has announced a registered direct offering with a single institutional investor, raising approximately $8 million in gross proceeds. The company sold 8,000,000 ordinary shares along with warrants to purchase an additional 8,000,000 shares at a combined price of $1.00 per share and warrant. The net proceeds from this offering will be utilized for working capital and general corporate purposes, with A.G.P./Alliance Global Partners acting as the sole placement agent.
Nano-X Imaging Ltd. Announces Pricing of a $8 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nano-X Imaging Ltd. (Nasdaq: NNOX) announced a registered direct offering priced at-the-market under Nasdaq rules, totaling $8 million. The company entered into a securities purchase agreement with a single long-term institutional investor for the purchase of 8,000,000 Ordinary Shares and warrants. The proceeds are intended for working capital and general corporate purposes, with A.G.P./Alliance Global Partners acting as the sole placement agent.
Nano-X sets $1 combined price for shares and accompanying warrants
Nano-X Imaging Ltd. (Nasdaq: NNOX) announced a registered direct offering with a single institutional investor to sell 8,000,000 Ordinary Shares (or prefunded warrants) and warrants for an additional 8,000,000 shares at a combined price of $1.00 per share and accompanying warrant. The warrants have a $1.15 exercise price, become exercisable in six months, and expire in five years. The offering is expected to generate approximately $8 million in gross proceeds, which will be used for working capital and general corporate purposes, with A.G.P./Alliance Global Partners acting as the sole placement agent.
Nano-X Imaging Ltd. Announces Pricing of a $8 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nano-X Imaging Ltd. (Nasdaq: NNOX) announced a registered direct offering of 8,000,000 Ordinary Shares and warrants for $8 million to a single long-term institutional investor. The shares and accompanying warrants are priced at $1.00 per unit, with warrants exercisable at $1.15 per share for five years. The company intends to use the net proceeds for working capital and general corporate purposes, with closing expected around August 7, 2026.
Levi & Korsinsky Reminds Nano-X Imaging Ltd. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 11, 2026 - NNOX
Levi & Korsinsky is reminding investors of Nano-X Imaging Ltd. (NASDAQ: NNOX) about a pending securities class action lawsuit, with a lead plaintiff deadline of August 11, 2026. The lawsuit stems from alleged losses after Nano-X disclosed a significant quarterly net loss, an impairment charge, and a manufacturing restructuring, causing a 24.39% stock decline. Institutional investors who held NNOX positions between March 31, 2025, and April 17, 2026, are encouraged to evaluate their eligibility to serve as lead plaintiff.
Deadline Alert: Nano-X Imaging Ltd. (NNOX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP reminds investors of Nano-X Imaging Ltd. (NNOX) about an upcoming August 11, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges that Nano-X made materially false and misleading statements between March 31, 2025, and April 17, 2026, regarding its operational efficiency, product demand, increased operating expenses, and cash burn. Investors who suffered losses are urged to contact the law firm to potentially recover their investments under federal securities laws.
Levi & Korsinsky Reminds Nano-X Imaging Ltd. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 11, 2026 - NNOX
Levi & Korsinsky, LLP is reminding investors of Nano-X Imaging Ltd. (NNOX) about a pending class action lawsuit with a lead plaintiff deadline of August 11, 2026. The lawsuit stems from alleged losses after Nano-X disclosed a significant net loss, an impairment charge, and manufacturing restructuring, causing a 24.39% stock decline. Institutional investors who held NNOX shares between March 31, 2025, and April 17, 2026, are encouraged to evaluate their options for lead plaintiff status to oversee the litigation.
Shareholders who lost money in shares Nano-X Imaging Ltd.
Wolf Haldenstein Adler Freeman & Herz LLP reminds investors of Nano-X Imaging Ltd. (NASDAQ: NNOX) about a class action lawsuit for those who bought securities between March 31, 2025, and April 17, 2026, and suffered losses. The lawsuit alleges that Nano-X overstated efficiency and demand, leading to significant operating expenses and a stock price drop after reporting Q4 2025 financial results. The lead plaintiff deadline is August 11, 2026.
Deadline Alert: Nano-X Imaging Ltd. (NNOX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is urging Nano-X Imaging Ltd. (NNOX) shareholders who lost money to contact them regarding a securities fraud lawsuit. The lawsuit alleges that Nano-X made materially false or misleading statements between March 31, 2025, and April 17, 2026, failing to disclose issues with operational efficiency, product demand alignment, increased operating expenses, and the likelihood of significant restructuring and impairment charges. Investors have until August 11, 2026, to file a lead plaintiff motion.
Shareholders who lost money in shares Nano-X Imaging Ltd.
Wolf Haldenstein Adler Freeman & Herz LLP is reminding investors of Nano-X Imaging Ltd. (NASDAQ: NNOX) about a class action lawsuit with an August 11, 2026, lead plaintiff deadline. The lawsuit alleges that Nano-X overstated efficiency, demand, and concealed increased operating expenses and cash burn, leading to a significant stock price drop after Q4 2025 financial results revealed a $33.4 million net loss and a restructuring initiative. The firm encourages affected investors to contact them.
Portnoy Law Firm Announces Class Action on Behalf of Nano-X Imaging Ltd. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Nano-X Imaging Ltd. (NASDAQ: NNOX) who purchased securities between March 31, 2025, and April 17, 2026. The lawsuit alleges that Nano-X overstated its operational efficiency and product demand, while experiencing increased operating expenses and cash burn, leading to materially false and misleading public statements. Investors have until August 11, 2026, to file a lead plaintiff motion.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2026 in Nano-X Imaging Ltd. Lawsuit - NNOX
The Gross Law Firm is reminding shareholders of Nano-X Imaging Ltd. (NNOX) who purchased shares between March 31, 2025, and April 17, 2026, about a lead plaintiff deadline of August 11, 2026, in a class action lawsuit. The lawsuit alleges that Nano-X issued materially false and misleading statements regarding its operational efficiency, product demand, and increased operating expenses, leading to artificial inflation of its stock. Shareholders are encouraged to register to participate in the case, with no cost or obligation.
Nano-X Imaging (NNOX) holder prepares to sell 20,000 vested RSU shares
Nano-X Imaging Ltd. (NNOX) has announced a proposed sale of 20,000 ordinary shares by a holder. These shares were acquired on November 22, 2024, upon the vesting of Restricted Stock Units (RSUs) without cash consideration. The sale will be executed on Nasdaq through Oppenheimer & Co. Inc.
Nano-X Imaging (NNOX) CFO Guy Nathansohn files first Form 3
Nano-X Imaging Ltd.'s CFO, Guy Nathansohn, has filed his initial Form 3, which reports his status as an officer subject to insider disclosure rules. This filing confirms his position but indicates no transactions or derivative positions at this time. The document also includes a Power of Attorney, Exhibit 24.1, authorizing specific individuals to handle certain SEC filings on his behalf.
Bronstein, Gewirtz & Grossman LLC Urges Nano-X Imaging Ltd.
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Nano-X Imaging Ltd. (NNOX), alleging the company made materially false and misleading statements regarding its operations and demand for its products, leading to increased operating expenses and cash burn. Investors who purchased Nano-X securities between March 31, 2025, and April 17, 2026, are encouraged to join the lawsuit, with an August 11, 2026, deadline to request appointment as lead plaintiff. The firm represents investors on a contingency fee basis.
NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP is reminding investors of a class action lawsuit against Nano-X Imaging Ltd. (NASDAQ: NNOX) for alleged securities fraud between March 31, 2025, and April 17, 2026. The lawsuit claims Nano-X made false and misleading statements about product demand and operational efficiency, leading to increased cash burn and investor losses. Shareholders who suffered losses during this period are encouraged to contact SBS Law to discuss lead plaintiff appointments by the August 11, 2026 deadline.
NNOX Shareholder Alert: August 11, 2026 Lead Plaintiff
Levi & Korsinsky, LLP has issued a shareholder alert for investors in Nano-X Imaging Ltd. (NNOX) regarding a securities class action lawsuit. The lawsuit stems from a significant stock drop after Nano-X disclosed a $17.5 million impairment charge and a pivot to outsourced manufacturing, following allegedly misleading statements about manufacturing efficiency. Investors who purchased NNOX securities between March 31, 2025, and April 17, 2026, may qualify to recover losses, with an August 11, 2026, deadline to apply for lead plaintiff.
NNOX Shareholder Alert: August 11, 2026 Lead Plaintiff
Levi & Korsinsky, LLP has issued a shareholder alert for Nano-X Imaging Ltd. (NNOX) investors, announcing a securities class action lawsuit with an August 11, 2026 lead plaintiff deadline. The alert follows a significant stock drop after Nano-X disclosed a $17.5 million impairment charge and a manufacturing restructuring, leading Ladenburg Thalmann to cut its price target. The lawsuit alleges that management made misleading statements about manufacturing efficiency and demand alignment during the class period of March 31, 2025, to April 17, 2026.
NNOX Deadline: Rosen Law Firm Urges Nano-X Imaging Ltd. (NASDAQ: NNOX) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
The Rosen Law Firm is reminding investors who purchased Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between March 31, 2025, and April 17, 2026, about a class action lawsuit. The lawsuit alleges that Nano-X made false and misleading statements regarding its operational efficiency and product demand, leading to increased operating expenses and cash burn. Shareholders with losses over $100,000 are urged to contact the firm by the August 11, 2026, deadline to potentially serve as lead plaintiff.
